Roche to present important new data for HER2-positive breast cancer at 2011 San Antonio Breast Cancer Symposium

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it will present results from studies of its investigational medicine pertuzumab in HER2-positive breast cancer, at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 6-10 2011.

This includes data from the first randomised Phase III study of pertuzumab in combination with Herceptin and docetaxel chemotherapy (CLEOPATRA). The mechanisms of action of pertuzumab and Herceptin are believed to complement each other as both bind to the HER2 receptor but on different regions.

“We are making additional substantial progress against HER2-positive breast cancer, a disease for which we have already dramatically changed the standard of care and improved patient outcomes," said Hal Barron, M.D., chief medical officer and head, Global Product Development. “Data at this conference reaffirm our commitment to discovering new treatments for HER2-positive breast cancer."